Onco-Innovations signs LOI with Ifowonco for option, global license to LAG-3 small-molecule program

• Onco-Innovations signed a non-binding LOI with Ifowonco to negotiate an exclusive option and worldwide license for a LAG-3 small-molecule inhibitor program.
• Deal targets an oral LAG-3 immune checkpoint inhibitor platform, positioned as an alternative to intravenous monoclonal-antibody LAG-3 therapies.
• Parties plan to evaluate combinations with ONC010, aiming to pair DNA damage response inhibition with LAG-3 blockade across solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608191840ACCESSWRNAPR_____1209568) on August 19, 2026, and is solely responsible for the information contained therein.